Author

N. Niu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

C. Liu· 3 shared D. Wang· 2 shared H. Li· 2 shared J. Bu· 2 shared K. Bi· 2 shared L. SuniD· 2 shared Q. Ma· 2 shared X. Jiang· 2 shared

Activity by Year

2021-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. Liu

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Multilevel regulation of NF-kappa B signaling by NSD2 suppresses Kras-driven pancreatic tumorigenesis

W. Feng, N. Niu, P. Lu, H. Rao, Z. Chen, W. Zhang, C. Ma, C. Liu, Y. Xu, W.-Q. Gao, J. Xue, L. Li

This study shows NSD2 acts as a tumor suppressor in Kras-driven pancreatic cancer by regulating NF-kappa B signaling through multiple mechanisms.

bioRxiv · Sep 11, 2023 · PreprintCancer Biology

CDH1 loss defines distinct diffuse-gastric cancer subtype with T cell exhaustion and EZH2 regulon activation

G. Zou, Y. Huang, S. Zhang, K.-P. Ko, B. J. Kim, J. Zhang, V. Venkatesan, M. P. Pizzi, S. Jun, N. Niu, H. Wang, S. Song, J. A. Ajani, J.-I. Park

This study identifies two distinct subtypes of diffuse-type gastric cancer associated with CDH1 loss, highlighting T cell exhaustion and EZH2 regulon activation.

bioRxiv · Mar 23, 2023Cancer Biology

Dalpiciclib Partially Abrogates ER Signaling Activation Induced by Pyrotinib In HER2+HR+ Breast Cancer

C. Liu, J. Bu, Y. Zhang, N. Niu, K. Bi, L. Sun, X. Qiao, Y. Wang, Y. Zhang, X. Jiang, D. Wang, Q. Ma, H. Li

The paper investigates how dalpiciclib affects ER signaling activation induced by pyrotinib in HER2+HR+ breast cancer and identifies CALML5 as a risk factor.

eLife · Jan 5, 2023Peer-reviewedCancer Biology

Dalpiciclib and Pyrotinib Exert Synergistic Antitumor Effects in Triple Positive Breast Cancer

J. Bu, Y. Zhang, N. Niu, K. Bi, L. Sun, X. Qiao, Y. Wang, Y. Zhang, X. Jiang, D. Wang, Q. Ma, H. Li, C. Liu

This study shows that combining dalpiciclib with pyrotinib is more effective than pyrotinib with tamoxifen in treating triple-positive breast cancer, with CALML5 as a potential biomarker.

bioRxiv · Oct 4, 2021 · PreprintCell Biology